CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Nephrogen Biotech
Company Type: Therapeutic development
Main focus: Developing gene therapies to treat kidney disease
Company stage: Pre-clinical
Diseases: Autosomal dominant polycystic kidney disease (ADPKD) and other kidney diseases
Genome-editing tool: CRISPR-Cas9
Funding stage: Non-equity Assistance
Location: New York, New York, USA
Website: www.nephrogenbiotech.com
Pipeline:
Partners:
Nephrogen is a pre-clinical biotech company developing curative gene therapies for kidney diseases, with a primary focus on autosomal dominant polycystic kidney disease (ADPKD). The company's platform combines CRISPR-Cas genome-editing technology with advanced nucleic acid delivery systems, including adeno-associated viruses (AAVs) and lipid nanoparticles (LNPs), to target kidney diseases at their genetic source. Nephrogen aims to address a significant unmet medical need, as ADPKD affects approximately 600,000 Americans and currently lacks effective treatment options. The company has established a broad patent portfolio to support its therapeutic development and future partnerships in the kidney disease space.
